Jasper Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 8, 2023 and accepted by EDGAR at Mar 8, 2023, 21:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2022-01-01 to 2022-12-31 | $34.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$51.2m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$37.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$1.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$1.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 36,482,761 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$45.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-12-31 | $38.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $41.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $48.4m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $7.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $12.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $36.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-23-018542. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.